ArticleOncology2022

Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma.

Yusuke Kawamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.